@article{10539,
  keywords = {Cprd, Immune checkpoint inhibitors, Lung cancer, Study eligibility, Tyrosine kinase inhibitors},
  author = {A. van Veelen and S. Abtahi and P. Souverein and J. Driessen and O. Klungel and A. Dingemans and R. van Geel and F. de Vries and S. Croes},
  title = {Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors},
  year = {2022},
  journal = {Cancer Epidemiol},
  volume = {78},
  edition = {2022/04/17},
  pages = {102149},
  isbn = {1877-7821},
  doi = {10.1016/j.canep.2022.102149},
  note = {1877-783x
van Veelen, Ard
Abtahi, Shahab
Souverein, Patrick
Driessen, Johanna H M
Klungel, Olaf H
Dingemans, Anne-Marie C
van Geel, Robin
de Vries, Frank
Croes, Sander
Journal Article
Netherlands
Cancer Epidemiol. 2022 Apr 13;78:102149. doi: 10.1016/j.canep.2022.102149.},
  language = {eng},
}